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Edited by Judit Ova´diAbstract Mono-O-glycosylations post-translationally regulate
the activity of nucleocytoplasmic proteins. We showed that
glucosamine and an inhibitor of deglycosylation (PUGNAc) in-
duced O-glycosylation of FoxO1, resulting in increased expres-
sion of a glucose-6-phosphatase reporter gene. This eﬀect was
independent of FoxO1 re-localisation, since it was also observed
with constitutively nuclear FoxO1-AAA mutant. Moreover, in
HepG2 cells, glucosamine and PUGNAc have a synergistic eﬀect
on the glucose-6-phosphatase reporter gene, and this eﬀect was
inhibited by FoxO1 siRNAs. Since glucose-6-phosphatase plays
a key role in hepatic glucose production, our observation may be
of importance with regard to glucotoxicity associated with
chronic hyperglycaemia in diabetes.
 2008 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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In mammals, blood glucose concentrations are kept within
narrow ranges, despite important variations in the nutritional
status during the day. The importance of this regulation is
underlined by the adverse consequences of chronic hyperglyca-
emia. Indeed, in insulin resistant patients, hyperglycaemia per
se has deleterious eﬀects (glucotoxicity) on insulin target
tissues and on pancreatic b-cells, initiating a vicious circle
that results in worsening of glucose intolerance and ﬁnally
appearance of type 2 diabetes. Although several diﬀerent
mechanisms appear to be involved, mono-O-glycosylation of
cytosolic and nuclear proteins represents an ever-growing area
of research in the ﬁeld [1,2]. The addition of N-acetylglucos-
amine (GlcNAc) on proteins is catalysed by O-linked b-N-acet-
ylglucosamine transferase (OGT). OGT uses UDP-GlcNAc,
produced by the hexosamine biosynthetic pathway, as a sub-Abbreviations: PUGNAc, O-(2-acetamido-2-deoxy-D-glucopyranosy-
lidene)amino-N-phenylcarbamate; GlcN, glucosamine; GlcNAc, N-
acetylglucosamine; OGT, O-linked b-N-acetylglucosamine transferase;
O-GlcNAcase, b-D-N-acetylglucosaminidase; WGA, wheat-germ
agglutinin; G6Pase, glucose 6-phosphatase
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to 5% of the glucose entering the cell is directed toward this
pathway. Therefore, OGT can be considered as a metabolic
sensor that modiﬁes proteins according to changes in glu-
cose availability [2]. These modiﬁcations can be rapidly
reversed by b-D-N-acetylglucosaminidase (O-GlcNAcase),
which removes the O-GlcNAc moiety from O-glycosylated
proteins. These modiﬁcations may be particularly important
in situations where glucose concentrations are altered, such
as type 2 diabetes and obesity [1,2].
Excessive hepatic glucose production is a major cause of
fasting hyperglycaemia in diabetes. The hydrolysis of glu-
cose-6-phosphate by glucose-6-phosphatase (G6Pase) is the
ﬁnal and obligatory step for the release of glucose into the cir-
culation. Insulin inhibits the expression of this enzyme, both in
cultured hepatocytes [3] and in animals [4], resulting in inhibi-
tion of hepatic glucose production. However, most surpris-
ingly, in cultured hepatocytes, high concentrations of glucose
increased G6Pase mRNA expression [5]. In partially pancre-
atectomized diabetic animals, hyperglycaemia per se also
increased the G6Pase mRNA expression, and this eﬀect was
reversed by phloridzin, which normalizes glycaemia indepen-
dently of insulin [4].
G6Pase gene expression is known to be under the control of
Forkhead Box Other-1 (FoxO1) trancription factor. Insulin,
through activation of protein kinase B (PKB), induces phos-
phorylation of FoxO1 on serine and threonine residues, result-
ing in its association with 14-3-3, exclusion from the nucleus
[6], decreased G6Pase expression and thereby inhibition hepa-
tic glucose production [7]. Whereas the role of FoxO1 in the
negative regulation of G6Pase expression by insulin is well
established, the potential involvement of FoxO1 in glucose-in-
duced G6Pase expression observed under chronic hyperglycae-
mic conditions has not been investigated yet. Since the activity
of several transcription factors can be regulated by O-glycosyl-
ation [2,8], this work was undertaken (i) to determine whether
FoxO1 is a target for O-glycosylation (ii) to evaluate the
potential involvement of O-glycosylation of FoxO1 in the reg-
ulation of G6Pase expression.2. Materials and methods
2.1. Chemicals and antibodies
All chemicals were from Sigma, except O-(2-acetamido-2-deoxy-D-
glucopyranosylidene)amino-N-phenylcarbamate (PUGNAc) (Carbo-
gen Amcis, Switzerland). Antibodies used in this work were as follows:blished by Elsevier B.V. All rights reserved.
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anti-O-GlcNAc (CTD110.6, Covance), anti-UBF (F-9, Santa-Cruz),
and anti-a-tubulin (DM1A, Sigma).
2.2. Cell culture, transfection and treatments
HEK293 and HepG2 cells were maintained in DMEM containing
25 mM glucose and 10% fetal calf serum (FCS). Cells were transfected
using FuGENE 6 (Roche) for cDNA or Lipofectamine 2000 (Invitro-
gen) for siRNAs.
Unless otherwise speciﬁed, cell treatments were performed as fol-
lows. Cells were grown in DMEM containing 5.5 mM glucose and
10% FCS. At the beginning of the treatment, this medium was replaced
by the same medium containing only 1% FCS and diﬀerent agents. For
immunoprecipitation and wheat-germ agglutinin (WGA) precipitation,
cells were treated for 24 h with either 100 lM PUGNAc or 25 mM glu-
cose, or for 2 h with 5 mM glucosamine (GlcN). Dual-luciferase assays
in HEK293 cells were performed after 24 h treatment with 100 lM
PUGNAc. Luciferase assays in HepG2 cells were performed after
48 h treatment with 100 lM PUGNAc and/or 0.5 mM GlcN. For
the study of mRNA expression, HepG2 cells were treated for 24 h with
100 lM PUGNAc or 0.5 mM GlcN.
2.3. Immunoprecipitation and WGA precipitation
Approximately 2 · 106 cells were lysed in buﬀer containing 50 mM
Tris–HCl (pH 8), 137 mM NaCl, 10% (v/v) glycerol, 1% (v/v) NP40,
50 mM NaF, 10 mM di-sodium b-glycerophosphate, 1 mM Na3VO4,
1 mM streptozotocin and a protease inhibitor cocktail (pepstatin, anti-
pain, leupeptin, aprotinin and AEBSF, 1 lg/ml each). For immunopre-
cipitation, clariﬁed extracts (400 lg of proteins) were incubated with
anti-GFP antibody and protein G-sepharose beads for 3 h at 4 C.
For WGA precipitation, cell extracts (250 lg of proteins) were incu-
bated with 30 ll of succinylated-WGA agarose beads (Vector Labora-
tories) for 2 h at 4 C. After 4 washes, proteins were eluted from the
beads in Laemmli buﬀer, separated by SDS–PAGE and revealed by
Western blotting using Enhanced Chemoluminescence (ECL, Amer-
sham).
2.4. Luciferase assay and dual-luciferase assay
Luciferase assays (Promega) were performed using HepG2 cells sta-
bly transfected with the luciferase reporter construct containing the
(299/+57) promoter region of the human G6Pase gene (polyclonal
cell line [9]). Each determination was performed in triplicate and
expressed as luciferase activity per lg of protein.
Dual-luciferase assay (Promega) were performed using HEK293
cells transiently co-transfected with a plasmid containing the ﬁreﬂy
luciferase reporter gene driven by the (299/+57) promoter region of
human G6Pase gene and a plasmid coding for Renilla luciferase to
normalize for transfection eﬃciency. Each determination was per-
formed in triplicate and expressed as Fireﬂy/Renilla luciferase activi-
ties.
2.5. Statistical analysis
Statistical analysis was carried out by ANOVA using Statview 5.0
software.3. Results
3.1. O-glycosylation of FoxO1 in HEK293 cells
To determine whether FoxO1 is subject to O-glycosylation,
HEK293 cells transfected with CFP-tagged FoxO1 were trea-
ted with glucosamine (GlcN), which promotes O-glycosylation
of proteins by increasing UDP-GlcNAc, and PUGNAc, which
inhibits deglycosylation by O-GlcNAcase. O-glycosylated pro-
teins were adsorbed on WGA-agarose beads and analysed by
Western blotting using an anti-FoxO1 antibody (Fig. 1A).
Two bands, corresponding to the molecular mass of untagged-
and CFP-tagged FoxO1 (approximately 80 kDa and 110 kDa,
respectively), could be detected. GlcN and PUGNAc both
increased the recovery of these proteins on WGA-beads(Fig. 1A, left panel), without aﬀecting the expression level of
endogenous or transfected FoxO1 proteins (Fig. 1A, right pa-
nel). These results suggested that FoxO1 is O-glycosylated
upon treatments that increase O-glycosylation or impair degly-
cosylation.
O-glycosylation of FoxO1 was further conﬁrmed in immu-
noprecipitation experiments. HEK293 cells transfected with
FoxO1-CFP were incubated with PUGNAc or GlcN.
FoxO1-CFP was immunoprecipitated with an anti-GFP anti-
body. In the absence of PUGNAc, a basal O-glycosylation sig-
nal could be detected. Both PUGNAc and GlcN markedly
increased O-glycosylation of FoxO1-CFP (Fig. 1B). Control
experiments (Supplementary Fig. S1) showed that CFP alone
was not O-glycosylated in cells treated with PUGNAc,
whereas FoxO1-CFP was markedly O-glycosylated in the same
experiments.
We also evaluated the eﬀect of glucose on the O-glycosyla-
tion of FoxO1. Cells transfected with FoxO1-CFP were grown
in medium containing 5.5 mM glucose for 48 h and then cul-
tured for a further 24 h in the presence of 5.5 mM glucose,
25 mM glucose or 5.5 mM glucose plus PUGNAc (Fig. 1C).
O-glycosylation level of FoxO1 was clearly increased in cells
cultured in 25 mM glucose compared to cells maintained in
5.5 mM glucose. However, the eﬀect of 25 mM glucose was
lower than the eﬀect of PUGNAc.
O-glycosylation can occur on regulatory phosphorylation
sites of proteins, thereby controlling their activity by ﬁne-tun-
ing their phosphorylation on Ser or Thr. Phosphorylation of
FoxO1 by PKB on Thr 24, Ser 256 and Ser 319 induces its
nuclear exclusion, thereby decreasing its transcriptional activ-
ity. Replacement of these residues with alanine results in con-
stitutive nuclear localisation and activity of the FoxO1-AAA
mutant. In order to determine whether mutation of these sites
impairs O-glycosylation of FoxO1, HEK293 cells transfected
with FoxO1-AAA were incubated in the presence of PUG-
NAc, GlcN or high-glucose concentrations (Fig. 1D). All three
treatments increased O-glycosylation of FoxO1-AAA, suggest-
ing that the phosphorylation sites involved in the control of
FoxO1 subcellular distribution are not major O-glycosylation
sites. In agreement with this notion, we observed that PUG-
NAc did not aﬀect the nuclear/cytosolic distribution of either
wild-type or FoxO1-AAA mutant (Supplementary Fig. S2).
To determine whether O-glycosylation of FoxO1 regulates
its transcriptional activity, HEK293 cells were transfected with
a reporter gene (G6Pase-luc) constituting of the 299/+57
fragment of the human G6Pase promoter driving the ﬁreﬂy
luciferase gene [6]. In control cells, PUGNAc had little or no
eﬀect on the luciferase activity (Fig. 2A). Co-transfection with
FoxO1 resulted in higher basal and PUGNAc-induced lucifer-
ase activities. Transfection with the constitutively active
FoxO1-AAA mutant resulted in a higher basal luciferase activ-
ity compared to wild-type FoxO1 (Fig. 2B), and PUGNAc fur-
ther increased this activity. These results, together with those
described in Fig. 1D and Supplementary Fig. S2, suggest that
O-glycosylation of FoxO1 may play an important role in the
control of G6Pase expression, independently of the phosphor-
ylation sites that control FoxO1 cellular distribution.
Since high-glucose concentrations increased O-glycosylation
of FoxO1, we also evaluated the eﬀect of glucose on the
G6Pase reporter-gene. We observed that in the presence of
25 mM glucose, the activity of the reporter gene was increased
in FoxO1 transfected cells (Supplementary Fig. S3). However,
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Fig. 1. O-glycosylation of FoxO1 in HEK 293 cells. (A) HEK293 cells transfected with either FoxO1-CFP or empty vector (pcDNA3) were treated
with glucosamine (GlcN) or PUGNAc. After cell lysis, glycosylated proteins were adsorbed on Wheat-germ agglutinin (WGA) beads and analysed
by Western blotting (WB) using anti-FoxO1 antibody. (B) Cells treated as in A were extracted, immunoprecipitated using anti-GFP antibody and
analysed by WB using anti-O-GlcNAc and anti-GFP antibodies. (C) HEK293 cells grown in 5.5 mM glucose were cultured for an additional 24 h in
5.5 mM glucose, 25 mM glucose or 5.5 mM glucose plus PUGNAc. (D) HEK293 cells transfected either with FoxO1-AAA-GFP or pcDNA3 were
treated with 25 mM glucose, PUGNAc or GlcN. Western blots are representative of 3 independent experiments.
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of PUGNAc on G6Pase reporter gene was higher than the ef-
fect of 25 mM glucose. The involvement of the O-glycosylation
signalling pathway was also demonstrated by co-transfection
of the G6Pase reporter-gene with OGT (Fig. 2C). Transfection
with OGT alone resulted in increased PUGNAc-stimulated
luciferase activity, and co-transfection with both FoxO1 and
OGT further increased these activities. These results further
demonstrated the dependence of the G6Pase promoter activity
on the O-glycosylation signalling pathway.
3.2. Regulation of G6Pase promoter by the O-glycosylation
pathway in HepG2 cells
To further study the regulation of the G6Pase promoter in a
more relevant cell model, we used HepG2 cells stably transfec-
ted with the G6Pase-luc reporter gene [9]. Cells were incubated
for 48 h with PUGNAc, GlcN or both (Fig. 3A). PUGNAc or
GlcN alone stimulated the activity of the reporter gene. More-
over, synergistic eﬀects were observed when both agents were
added together. As shown in Supplementary Fig. S4, these
treatments had similar eﬀects on G6Pase mRNA expression
in HepG2 cells measured by quantitative RT-PCR.Altogether, these results strongly support a role for the
O-glycosylation signalling pathway in the regulation of
G6Pase expression in liver derived cells. To conﬁrm that these
eﬀects were indeed mediated by FoxO1, a siRNA approach
was employed using two diﬀerent sequences (siRNAs 1 and
2) previously shown to inhibit FoxO1 expression by 80–90%
[10,11]. A similar inhibitory eﬃciency of these siRNAs on
FoxO1 expression in HepG2 cells was conﬁrmed by Western
blotting (Supplementary Fig. S5). HepG2 cells expressing the
G6Pase-luc reporter gene were transfected with control or
FoxO1 siRNAs. We observed that both siRNAs inhibit the
synergistic eﬀect of PUGNAc and GlcN on the activity of
the reporter gene (Fig. 3B). This result further conﬁrms the
involvement of FoxO1 in the regulation of G6Pase promoter
by the O-glycosylation pathway.4. Discussion
FoxO1 belongs to a family of transcription factors that mod-
ulate important cellular functions, by regulating the expression
of genes involved in apoptosis, cell cycle, oxidative stress, cell
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Fig. 2. Eﬀect of PUGNAc on G6Pase-luc reporter gene in HEK293 cells. HEK293 cells were co-transfected with G6Pase-luc reporter, Renilla
luciferase, pcDNA3, and (A) wild-type or (B) mutated FoxO1-AAA or (C) OGT with or without wild-type FoxO1. Transfected cells were treated or
not with PUGNAc for 24 h. Results are expressed as fold-increase in luciferase activity compared to untreated cells (left panel) or as PUGNAc-
induced increase in luciferase activity (right panel). Results are the means ± S.E.M. of 5–8 experiments (*, **, ***, P < 0.05, P < 0.01, P < 0.001,
respectively, N.S., not signiﬁcative).
832 M. Kuo et al. / FEBS Letters 582 (2008) 829–834diﬀerentiation and glucose metabolism. These factors are reg-
ulated by several post-translational modiﬁcations, including
phosphorylation, acetylation as well as mono- and poly-ubiq-
uitination. In this work, we showed that FoxO1 is also subject
to O-glycosylation, resulting in an increase in its transcrip-
tional activity on the G6Pase promoter. Several transcriptionfactors are subject to O-glycosylation that regulates the expres-
sion of their target genes through diﬀerent mechanisms [8]. For
instance, O-glycosylation augments the amount of Sp1 tran-
scription factor by decreasing its susceptibility to proteaso-
mal degradation, resulting in increased expression of its
target genes [12]. In the present study, neither transfected
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Fig. 3. Eﬀect of PUGNAc and glucosamine on G6Pase promoter activity in HepG2 cells. (A) HepG2 cells stably expressing the G6Pase-luc reporter
gene were treated with PUGNAc, GlcN, or both for 48 h. Results are expressed as fold-increase in luciferase activity compared to untreated cells and
correspond to the means ± S.E.M. of 5–8 experiments. (B) Negative control siRNA or two distinct siRNAs targeting FoxO1 (10 and 20 pmol per
4 · 104 cells) were transfected into HepG2 cells stably expressing the G6Pase-luc reporter. Cells were treated with PUGNAc plus GlcN for 48 h and
luciferase activities were then analysed. Results are expressed as fold-increase in luciferase activity compared to untreated cells and correspond to the
means ± S.E.M. of 3–6 experiments (*, **, ***, P < 0.05, P < 0.01, P < 0.001, respectively, N.S., not signiﬁcative).
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PUGNAc or GlcN treatment (Fig. 1A). Changes in the nuclear
versus cytoplasmic localisation of transcription factors have
also been observed upon O-glycosylation [8]. However, we ob-
served that O-glycosylation of FoxO1 increased its activityindependently of its subcellular localisation (Fig. 2B and Sup-
plementary Fig. S2). O-glycosylation can also aﬀect tran-
scription factors by modifying key residues involved in their
interaction with co-activators, as shown for Stat5–CBP
interaction [13]. Alternatively, O-glycosylation can induce
834 M. Kuo et al. / FEBS Letters 582 (2008) 829–834important conformational changes within transcription fac-
tors, which may have a direct impact on their activity, as dem-
onstrated for the estrogen receptor [14]. Clearly, identiﬁcation
and site-directed mutagenesis of the residue(s) that are O-gly-
cosylated, will constitute necessary steps for elucidation of
the mechanisms underlying FoxO1 regulation by O-glycosyla-
tion.
The observation that O-glycosylation of FoxO1 results in in-
creased expression of G6Pase gene may have considerable
implications with regards to pathological situations such as
diabetes and obesity. Indeed, chronic hyperglycaemia may
cause abnormal O-glycosylation of FoxO1 in obese or diabetic
patients, inducing over-expression of G6Pase, increased hepa-
tic glucose production and worsening of glucose intolerance.
Moreover, chronic hyperglycaemia also has deleterious eﬀects
on the pancreas. High-glucose concentrations are known to re-
duce survival and increase apoptosis of b-cells, both in vitro
and in animals. FoxO1 is known to control proliferation, sur-
vival and apoptosis of various cell types, including pancreatic
b-cells [15]. Thus, O-glycosylation of FoxO1, through activa-
tion of genes involved in growth arrest and apoptosis, could
also play a role in alterations of b-pancreatic function in dia-
betes.
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